Theravance Biopharma, Inc. 8-K

What Happened

• Theravance Biopharma reported in an 8‑K (filed March 30, 2026) that on March 27, 2026 its subsidiaries and Mylan entered into a Settlement Agreement with Mankind Pharma Ltd. and Lifestar Pharma LLC to resolve Hatch‑Waxman patent litigation over YUPELRI® (revefenacin) inhalation solution.
• The dispute involved U.S. Patent Nos. 11,484,531; 12,048,692; and 12,285,417 (the “Patents‑in‑Suit”), which a Theravance entity owns and for which Mylan is the exclusive sub‑licensee.

Key Details

• Settlement date: March 27, 2026; 8‑K filed March 30, 2026.
• Under the agreement, Theravance and Mylan granted Mankind a royalty‑free, non‑exclusive, non‑sublicensable, non‑transferable license to make and market Mankind’s generic YUPELRI® in the U.S. on or after the Licensed Launch Date of April 23, 2039.
• The settlement resolves all pending Hatch‑Waxman litigation between the parties over YUPELRI® (revefenacin) ANDA filings.
• As required by law, the settlement is subject to review by the U.S. Department of Justice and the Federal Trade Commission.

Why It Matters

• The agreement removes near‑term litigation uncertainty by settling the ANDA challenge, while preserving exclusivity for YUPELRI® in the U.S. through the licensed launch date of April 23, 2039.
• There are no monetary terms disclosed in the filing; investors should note the practical effect is delayed generic entry until the agreed date (subject to regulatory review), which may support product revenue for the duration of the patents.